Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variantsTingting Li, Aishun Jin, Xiaojian Han et al.|Nature Communications|2021Cited by 51
Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)Claire Harrison, Vincent Ribrag, Jean‐Jacques Kiladjian et al.|Blood|2015Cited by 39
A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2Xiaojian Han, Aishun Jin, Yingming Wang et al.|Frontiers in Immunology|2021Cited by 34
Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk MyelofibrosisJean‐Jacques Kiladjian, Claire Harrison, Alessandro M. Vannucchi et al.|Blood|2014Cited by 14
A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBDXiaojian Han, Aishun Jin, Yingming Wang et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 12